Premium
Same sibling marrow following cord allogeneic transplantation as therapy for second relapse acute promyelocytic leukemia in a pediatric patient
Author(s) -
De Oliveira Satiro N.,
Kao Roy L.,
Pham Andrew,
Smith LaMarr Taylor,
Kempert Pamela,
Moore Theodore B.
Publication year - 2016
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.12677
Subject(s) - medicine , sibling , acute promyelocytic leukemia , transplantation , complete remission , leukemia , bone marrow transplantation , pediatrics , oncology , chemotherapy , psychology , developmental psychology , retinoic acid , biochemistry , chemistry , gene
Optimal therapy for relapsed APL in pediatric patients is controversial. Allogeneic HSCT is an alternative, with event‐free survival of 70–75%. We report a pediatric patient with APL who relapsed 28 months after CBT from her sibling and then was treated with BMT from the same donor. Bone marrow was selected for higher cell dose, donor availability, and partial donor chimerism. Persistent molecular remission was achieved, currently at 65 months after BMT. This case suggests the potential role of GVL activity in APL and illustrates the use of different cell sources from the same donor in allogeneic transplantation for pediatric patients.